Literature DB >> 11531258

TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe.

P Tanière1, G Martel-Planche, J C Saurin, C Lombard-Bohas, F Berger, J Y Scoazec, P Hainaut.   

Abstract

In Europe, high incidence rates of oesophageal squamous cell carcinoma (SCCE) are observed in western France (Normandy and Brittany) and in north-eastern Italy. Analysis of TP53 mutations in tumours from these regions has shown a high prevalence of mutations at A:T basepairs that may result from DNA damage caused by specific mutagens. However, the spectrum of TP53 mutations in regions of low incidence is unknown. We report here TP53 mutation analysis in 33 SCCE collected in Lyon, an area of low incidence. These tumours were also examined for MDM2 and P63 amplification, and for expression of p16(INK4a/CDKN2a), cyclin E, p27(Kipl)and Cox2. TP53 mutations were detected in 36% of the cases (12/33). In contrast with regions of high incidence, the mutation spectrum did not show a high prevalence of mutations at A:T base pairs. P63 was amplified in 5/32 cases tested (15.5%). No amplification of MDM2 was found. Expression studies revealed frequent loss of p16(INK4a/CDKN2a)(46%) and p27(Kipl)(25%) expression, and frequent overexpression of Cyclin E (70%) and Cox2 (42%). Overall, these results indicate that in Europe, SCCE from areas of high and low incidence present a similar pattern of molecular alterations but differ by the type of TP53 mutations. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531258      PMCID: PMC2364124          DOI: 10.1054/bjoc.2001.1990

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.

Authors:  W Biernat; P Kleihues; Y Yonekawa; H Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  1997-02       Impact factor: 3.685

2.  Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer.

Authors:  A Itami; Y Shimada; G Watanabe; M Imamura
Journal:  Oncology       Date:  1999-11       Impact factor: 2.935

3.  Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.

Authors:  Q S Wang; C L Sabourin; H Wang; G D Stoner
Journal:  Carcinogenesis       Date:  1996-08       Impact factor: 4.944

4.  Acetaldehyde production by non-pathogenic Neisseria in human oral microflora: implications for carcinogenesis in upper aerodigestive tract.

Authors:  M Muto; Y Hitomi; A Ohtsu; H Shimada; Y Kashiwase; H Sasaki; S Yoshida; H Esumi
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

5.  Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.

Authors:  P Tanière; G Martel-Planche; D Maurici; C Lombard-Bohas; J Y Scoazec; R Montesano; F Berger; P Hainaut
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in south Thailand.

Authors:  P Tanière; G Martel-Planche; P Puttawibul; A Casson; R Montesano; A Chanvitan; P Hainaut
Journal:  Int J Cancer       Date:  2000-10-15       Impact factor: 7.396

7.  Changing pattern of oesophageal cancer incidence in France.

Authors:  G Launoy; J Faivre; P Pienkowski; C Milan; M Gignoux; D Pottier
Journal:  Int J Epidemiol       Date:  1994-04       Impact factor: 7.196

8.  Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations.

Authors:  M C Hollstein; L Peri; A M Mandard; J A Welsh; R Montesano; R A Metcalf; M Bak; C C Harris
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

9.  Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas.

Authors:  A Esteve; T Lehman; W Jiang; I B Weinstein; C C Harris; A Ruol; A Peracchia; R Montesano; M Hollstein
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

10.  TP53 gene mutation profile in esophageal squamous cell carcinomas.

Authors:  M P Audrézet; M Robaszkiewicz; B Mercier; J B Nousbaum; J P Bail; E Hardy; A Volant; P Lozac'h; J F Charles; H Gouéron
Journal:  Cancer Res       Date:  1993-12-01       Impact factor: 12.701

View more
  10 in total

1.  Inhibition of adenovirus-mediated p27kip1 gene on growth of esophageal carcinoma cell strain.

Authors:  Qing-Ming Wu; Jie-Ping Yu; Qiang Tong; Xiao-Hu Wang; Guo-Jian Xie
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 2.  Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.

Authors:  Yongjing Liu; Zhaohui Xiong; Andrea Beasley; Thomas D'Amico; Xiaoxin Luke Chen
Journal:  Ann N Y Acad Sci       Date:  2016-07-11       Impact factor: 5.691

3.  Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.

Authors:  Orit Karni-Schmidt; Mireia Castillo-Martin; Tian Huai Shen; Tian HuaiShen; Nataliya Gladoun; Josep Domingo-Domenech; Marta Sanchez-Carbayo; Yingchun Li; Scott Lowe; Carol Prives; Carlos Cordon-Cardo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

4.  Adenovirus expressing p27kip1 suppresses growth of established esophageal carcinoma xenografts.

Authors:  Wei-Guo Zhang; Qing-Ming Wu; Jie-Ping Yu; Qiang Tong; Guo-Jian Xie; Xiao-Hu Wang; Sheng-Bao Li
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

5.  Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells.

Authors:  Wei-Guo Zhang; Jie-Ping Yu; Qing-Ming Wu; Qiang Tong; Sheng-Bao Li; Xiao-Hu Wang; Guo-Jian Xie
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 6.  Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.

Authors:  Jean-Pierre Cosyns
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran.

Authors:  Behnoush Abedi-Ardekani; Farin Kamangar; Masoud Sotoudeh; Stephanie Villar; Farhad Islami; Karim Aghcheli; Dariush Nasrollahzadeh; Noushin Taghavi; Sanford M Dawsey; Christian C Abnet; Stephen M Hewitt; Saman Fahimi; Farrokh Saidi; Paul Brennan; Paolo Boffetta; Reza Malekzadeh; Pierre Hainaut
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

Review 8.  The potential of molecular markers to improve interventions through the natural history of oesophageal squamous cell carcinoma.

Authors:  Nathalia Meireles da Costa; Sheila Coelho Soares Lima; Tatiana de Almeida Simão; Luis Felipe Ribeiro Pinto
Journal:  Biosci Rep       Date:  2013-08-14       Impact factor: 3.840

9.  SOX2 amplification and chromosome 3 gain significantly impact prognosis in esophageal squamous cell carcinoma.

Authors:  Xin Wang; Xiaowen Ge; Haixing Wang; Jie Huang; Qi Song; Chen Xu; Zhengzeng Jiang; Jieakesu Su; Hao Wang; Lijie Tan; Dongxian Jiang; Yingyong Hou
Journal:  Ann Transl Med       Date:  2021-02

10.  p63 regulates cell proliferation and cell cycle progression‑associated genes in stromal cells of giant cell tumor of the bone.

Authors:  Carol Po Ying Lau; Patrick Kwok Shing Ng; Man Shan Li; Stephen Kwok Wing Tsui; Lin Huang; Shekhar Madhukar Kumta
Journal:  Int J Oncol       Date:  2012-12-03       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.